MMR-D is also suggested as a prognostic marker in colorectal cancer, where MMR-D predicts favorable disease outcome.9 In endometrial cancer, no significant difference in survival for MMR-D and MMR-proficient (MMR-P) tumors is reported,10 but high levels of MSH-6 independently predict poor survival.11 For MSH-2, high expression is related to poor outcome in oral squamous carcinoma.12 The prognostic impact of differential MMR expression has, to our knowledge, not previously been explored in cervical cancer. This evidence concerns the gene MSH2 and cervical carcinoma.